Integrated Biopharma Inc has released its financial results for the third quarter of 2026, as detailed in its recent filing. This report is significant as it illustrates the company's performance in the competitive pharmaceutical preparations sector.

Integrated Biopharma Inc, listed under the ticker INBP on the OTC exchange, operates within the pharmaceutical preparations industry, classified under SIC code 2834. The company is incorporated in Delaware and has been filing with the SEC as a non-accelerated filer and smaller reporting company.

The filing, dated November 13, 2026, provides insights into the company's financial health as of September 30, 2026. It highlights various operational metrics and financial positions that are crucial for stakeholders. However, specific details on revenue and profit margins were not available in the SEC filing.

Integrated Biopharma's performance may influence its stakeholders, including investors, employees, and customers. The pharmaceutical preparations industry is known for its competitive nature, and the company's ability to maintain its market presence is vital.

As for what’s next, the filing does not specify any upcoming actions or events following this report.

Financial Metrics and Shareholder Information

As of September 30, 2026, Integrated Biopharma Inc had 31,094,510 shares of common stock issued and outstanding, with a par value of $0.002 per share. The company has authorized a total of 50,000,000 shares of common stock. Additionally, the company holds 34,900 shares as treasury stock.

In terms of assets, Integrated Biopharma reported an operating lease right-of-use asset valued at $2,427,000 as of September 30, 2026, down from $2,686,000 at the end of the previous quarter. The operating lease liabilities were recorded at $1,018,000 for current liabilities and $1,457,000 for noncurrent liabilities.

The filing indicates that the company has two major customers, which reflects a concentration risk that could impact revenue stability.

Operational Insights

Integrated Biopharma operates in two reportable segments, highlighting its diversified business model within the pharmaceutical preparations sector. The company continues to navigate the competitive landscape of the industry, focusing on maintaining strong relationships with its major customers.

The filing does not provide specific revenue figures or detailed profit margins, which are critical for assessing the company's overall financial performance. Additionally, there are no updates on any strategic initiatives or future plans that may affect the company's trajectory.